Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Idebenone Prevents Human Optic Nerve Head Astrocytes From Oxidative Stress, Apoptosis, and Senescence by Stabilizing BAX/Bcl-2 Ratio
Idebenone loaded solid lipid nanoparticles: Calorimetric studies on surfactant and drug loading effects
Idebenone protects against oxidized low density lipoprotein induced mitochondrial dysfunction in vascular endothelial cells via GSK3 beta/beta-catenin signalling pathways
Idebenone Maintains Survival of Mutant Myocilin Cells by Inhibiting Apoptosis
Idebenone and Resveratrol Extend Lifespan and Improve Motor Function of HtrA2 Knockout Mice
Idebenone-loaded solid lipid nanoparticles for drug delivery to the skin: In vitro evaluation
Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial
Idebenone Protects against Retinal Damage and Loss of Vision in a Mouse Model of Leber%26apos;s Hereditary Optic Neuropathy
Idebenone treatment in patients with OPA1-mutant dominant optic atrophy
Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy
Idebenone Prevents Oxidative Stress, Cell Death and Senescence of Retinal Pigment Epithelium Cells by Stabilizing BAX/Bcl-2 Ratio
Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)
Idebenone Treatment In Leber's Hereditary Optic Neuropathy
Idebenone inhibition of glutamate release from rat cerebral cortex nerve endings by suppression of voltage-dependent calcium influx and protein kinase A
Idebenone Loaded Solid Lipid Nanoparticles Interact with Biomembrane Models: Calorimetric Evidence
Idebenone: A Review in Leber's Hereditary Optic Neuropathy
Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy
Idebenone Alleviates Neuroinflammation and Modulates Microglial Polarization in LPS-Stimulated BV2 Cells and MPTP-Induced Parkinson's Disease Mice
Idecade——21世纪设计杂谈
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 delta, for relapsed/refractory chronic lymphocytic leukemia
Idelalisib
Idelalisib at the Crossroads of B-Cell Lymphoproliferative Disorders
Idelalisib for the treatment of non-Hodgkin lymphoma
Idelalisib-associated Enterocolitis Clinicopathologic Features and Distinction From Other Enterocolitides
Idelalisib Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Idelalisib in the management of lymphoma
Idelalisib for the treatment of B-cell malignancies
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells
Idelalisib induces PUMA-dependent apoptosis in colon cancer cells
Idelalisib的合成工艺改进
Idelalisib induced CMV gastrointestinal disease: the need for vigilance with novel therapies
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy
Idelalisib may have the potential to increase radiotherapy side effects
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells
Idelalisib - A PI3K delta Inhibitor for B-Cell Cancers
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
Idelalisib for treatment of B-cell malignancies
Idelalisib: A Novel PI3K Inhibitor for Chronic Lymphocytic Leukemia
Idelalisib-related pneumonitis
Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma
Idempotent elements determined matrix algebras
Idempotent H.264 intraframe compression
Idempotence preserving maps between matrix spaces
Idempotent zero patterns
Idempotents in ring extensions
Idempotents of the Norton-Sakuma algebras
Idempotent states on compact quantum groups and their classification on U-q(2), SUq(2), and SOq(3)
Idempotents in beta S that are only products trivially